-
Mashup Score: 7Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement - 2 hour(s) ago
Key PointsCREBBP mutations create a zombie enzyme that inhibits EP300 and blunts CD40-responsive chromatin loading and enhancer activation.Enforcing CD40 s
Source: ashpublications.orgCategories: General Medicine NewsTweet
-
Mashup Score: 17Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups - 17 hour(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups https://t.co/04EL0vLxgx #clinicaltrialsandobservations #myeloidneoplasia https://t.co/AqNrEdAmru
-
-
Mashup Score: 35Can we harmonize classification of TP53 mutant MDS/AML? - 19 hour(s) ago
In this issue of Blood Advances, Shah et al1 provide an evidence-based proposal to harmonize the classification of TP53 mutant myelodysplastic neoplasms (M
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Can we harmonize classification of TP53 mutant MDS/AML? https://t.co/YIGx7jbjNi #InsideBloodAdvances #IBAs #myeloidneoplasia https://t.co/5xRJqqQNSU
-
-
Mashup Score: 8Silence of the myeloma clones: GPRC5D epigenetic regulation - 19 hour(s) ago
In this issue of Blood, Ma et al1 report on the loss of G protein–coupled receptor, class C, group 5, member D (GPRC5D) expression post–anti-GPRC5D chimeri
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @NBahlis: Silence of the myeloma clones: GPRC5D epigenetic regulation | Blood | American Society of Hematology https://t.co/2w2K5Mgstm
-
-
Mashup Score: 21Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia - 20 hour(s) ago
Care for patients with chronic lymphocytic leukemia has been revolutionized in the last decade as Bruton tyrosine kinase inhibitors and the B-cell lymphoma
Source: ashpublications.orgCategories: General Medicine NewsTweet-
#Hematology Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia #CLL | Blood | American Society of Hematology #lymsm #leusm #CLLsm https://t.co/ZifMUoSth5
-
-
Mashup Score: 9Volume 146 Issue 2 | Blood | American Society of Hematology - 20 hour(s) ago
Blood | 146 | 2 | July 2025
Source: ashpublications.orgCategories: General Medicine NewsTweet-
New Blood issue out now featuring: Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement https://t.co/zqQ9ZaSeHp https://t.co/98qHphFns6
-
-
Mashup Score: 9Throwing the microbiome out with the bathwater - 21 hour(s) ago
In this issue of Blood Advances, Darwin et al1 review a wide-ranging body of preclinical and early clinical studies that highlight the impact of antibiotic
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Throwing the microbiome out with the bathwater https://t.co/9X3OiX0gAw #InsideBloodAdvances #IBAs #immunobiologyandimmunotherapy #transplantation https://t.co/GPlm7Yi8Vp
-
-
Mashup Score: 10Younger haplo-donors improve older patient survival outcomes - 23 hour(s) ago
In this issue of Blood Advances, Nagayama et al1 report that patients aged ≥50 years who receive haploidentical (haplo) stem cell transplantation using pos
Source: ashpublications.orgCategories: General Medicine NewsTweet-
Younger haplo-donors improve older patient survival outcomes https://t.co/7QgF9Eqoe8 #InsideBloodAdvances #IBAs #transplantation
-
-
Mashup Score: 5COVID-19 and CLL in Sweden: lessons learned? - 1 day(s) ago
In this issue of Blood Advances, Hedberg et al1 describe the impact of COVID-19 in Sweden in patients with chronic lymphocytic leukemia (CLL) comparing the
Source: ashpublications.orgCategories: General Medicine NewsTweet-
COVID-19 and CLL in Sweden: lessons learned? https://t.co/alkpZPRb2z #InsideBloodAdvances #IBAs #lymphoidneoplasia https://t.co/OYUH5CFCLh
-
-
Mashup Score: 15TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation - 1 day(s) ago
Key PointsPatients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity.Transplant
Source: ashpublications.orgCategories: General Medicine NewsTweet-
TP53-mutant variant allele frequency and complex 5q/7q cytogenetics determine prognostic groups in MDS/AML for transplantation #bmtsm #leusm @MDAndersonNews @EJShpallMD @RichardChamplin @BloodPortfolio https://t.co/O4EpEmk7FR https://t.co/lRJvTYZt3b
-
Enforcing CD40 signaling through bispecific antibody engagement of CD4 T cells can overcome CREBBP mutations and induce lymphoma cell death. https://t.co/ZMm6mg1Csr #lymphoidneoplasia #immunobiologyandimmunotherapy https://t.co/8P6mJdNkhO